 በጥር 2019 ኤፍዲኤ ለታመሙ የካቦዛንቲኒብ ጽላቶች አፀደቀ hepatocellular ካርሲኖማ (ኤች.
Mu Januwale 2019, a FDA adavomereza mapiritsi a cabozantinib a odwala omwe ali ndi hepatocellular carcinoma (HCC) idathandizidwa kale ndi sorafenib.